Ivabradine and Post-revascularisation Microcirculatory Dysfunction

NCT ID: NCT02507050

Last Updated: 2018-08-17

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-03-31
• Study Completion Date: 2016-03-31

Brief Summary

The aim of the study is to test whether, in patients with angina and flow limiting epicardial coronary artery disease, pre-treatment with Ivabradine, as opposed to beta blockers, will reduce post percutaneous coronary intervention induced microvascular dysfunction.

Detailed Description

We will be recruiting patients with stable angina referred for percutaneous intervention (PCI) due to flow limiting coronary artery disease. All patients will be on an existing beta blocker prescription (standard first line angina therapy). Our hypothesis is that Ivabradine will attenuate microvascular dysfunction post PCI when compared to standard beta-blocker pre-treatment. We intend to test this in a randomised, open-label parallel arm study with a direct comparison between Ivabradine and beta-blockers (standard therapy). Patients will be randomised to receive either Ivabradine (and stop beta blockers) or continue beta blockers for 6 weeks prior to the PCI procedure. The primary endpoint will be IMR (index of microvascular resistance) post PCI, as a marker of microvascular dysfunction and procedural related myocardial injury. IMR is a potent marker of adverse outcome in STEMI patients and in ACS after PCI. Although this has yet to be assessed in the elective setting, a reduction in IMR with Ivabradine may indicate a potential to improve outcomes and lessen iatrogenic microvascular dysfunction post PCI. IMR is assessed using thermodilution catheters placed distal to the coronary stenosis and by producing hyperaemia. To assess the medium term effects on the microcirculation post PCI all patients will have a stress perfusion cardiac MRI 12 weeks post procedure. The secondary endpoint will be proportion of patients with coronary flow reserve (CFR) <2.0 in PCI territory (regional myocardial blood flow at hyperaemia by intravenous adenosine infusion compared to rest). We will also be assessing CFI (collateral flow index), as promotion of the collateral system is one method by which Ivabradine may lessen procedural related myocardial injury, and ΔIMR as the difference between IMR pre and post-PCI.

The measurement of cardiac troponins and use of cardiac MRI will facilitate the identification of peri-procedural myocardial injury and procedural related myocardial infarction as further secondary end points. The Seattle Angina Questionnaire will be used at 3 intervals to assess symptoms throughout the study. The total study length for each patient will be 18 weeks.

Conditions

Coronary Artery Disease; Angina

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intervention

Patients randomised to stop beta blockers and start Ivabradine. Initial dose of 5mg BD, titrated to 7.5mg BD if possible.

Group Type: EXPERIMENTAL

Ivabradine

Intervention Type: DRUG

To start Ivabradine 6 weeks prior to PCI.

Standard therapy

Bisoprolol given as standard beta blocker treatment i.e. Bisoprolol (maximum dose 10mg OD).

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Ivabradine

To start Ivabradine 6 weeks prior to PCI.

Intervention Type: DRUG

Other Intervention Names

Procoralan

Eligibility Criteria

Inclusion Criteria

1. Symptoms of Angina Pectoris

2. Angiographic evidence of epicardial coronary artery stenosis referred for PCI

3. Flow limiting lesion (Fractional Flow Reserve ≤0.80) in one of following locations (as defined in SYNTAX trial89):

1. Proximal or mid left anterior descending artery (LAD)

2. Proximal or mid dominant right coronary artery (RCA)

3. Proximal left circumflex artery (LCx) or 1ST Obtuse marginal Vessel

4. Existing beta blocker prescription

5. Echocardiogram performed within preceding 12 months

6. Patient consent

Exclusion Criteria

1. Previous myocardial infarction (MI) in target vessel myocardial territory or any MI in preceding 12 months (defined by patient history, ECG changes and evidence of regional wall motion abnormalities on echocardiography)

2. FFR>0.80 in target vessel at time of procedure

3. Requirement for Multi-vessel intervention in a single procedure

4. Any chronic total occlusion (100% epicardial occlusion) on angiography

5. Distal coronary artery stenosis or that affecting non-dominant RCA

6. Heart Rate <60 bpm at inclusion (assessed by 12 lead ECG after minimum 10 minutes rest period)

7. Any rhythm other than sinus rhythm

8. Sick sinus syndrome or high grade atrio-ventricular block

9. Permanent Pacemaker in situ

10. Congenital QT Syndrome

11. Intolerance or allergy to beta-blockers

12. Intolerance to Ivabradine

13. Additional (other than angina pectoris) indication for beta-blocker treatment e.g. ventricular tachycardia

14. Concurrent required use of rate-limiting drugs other than beta-blockers

15. The necessity of combination therapy with Ivabradine and bisoprolol to achieve heart rate control

16. Contraindication to Magnetic Resonance Imaging or IV adenosine

17. Severe impairment of renal function (eGFR<30ml/min)

18. Severe Liver Disease (Any worse than Grade A by Child-Pugh Classification)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Liverpool Heart and Chest Hospital NHS Foundation Trust

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Aleem Khand, MBChB MD

Role: PRINCIPAL_INVESTIGATOR

Liverpool Heart and Chest Hospital

Locations

Liverpool Heart and Chest Hospital

Liverpool, , United Kingdom

Countries

United Kingdom

Other Identifiers

1060

Identifier Type: -

Identifier Source: org_study_id